(Washington, D.C.) — Pharmaceutical Care Management Association President and CEO JC Scott issued the following statement on legislation passed by Congress to increase access to biosimilars, “The Ensuring Innovation Act” and the “Advancing Education on Biosimilars Act of 2021.”
“We applaud Congress for recognizing the need to increase competition in the prescription drug marketplace, especially for biosimilars, and we respectfully urge President Biden to sign the legislation into law.
Increasing prescriber and patient understanding of biosimilars, along with making it harder for drugs and biologics to gain exclusivity, are important steps to expanding the adoption of biosimilars and reducing overall drug costs.
Pharmacy benefit managers, PBMs, leverage competition among prescription drug products to reduce costs for patients. Increasing competition through the approval of more brand, generic, and biosimilar drug competitors will enable PBMs to more effectively lower prescription drug costs for patients, employers, government programs, and others.”
View PCMA’s 21 Policies to Reduce Prescription Drug Costs in 2021
###
PCMA is the national association representing America’s pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.
